Printer Friendly

i"?Trillium Therapeutics completes dosing of patients in phase one study of TTI-1612.

M2 PHARMA-May 20, 2013-i" Trillium Therapeutics completes dosing of patients in phase one study of TTI-1612(C)2013 M2 COMMUNICATIONS

Trillium Therapeutics, a wholly owned subsidiary of Stem Cell Therapeutics, has completed the dosing of patients with interstitial cystitis/bladder pain syndrome in its first phase study of TTI-1612, it was reported on Friday.

The study will assess the safety and tolerability profile of single ascending doses of TTI-1612. It involved 28 patients who were also evaluated for pharmacokinetics and changes in disease symptoms.

The company has developed TTI-1612 to correct the dysfunction and restore the bladder epithelium to a normal, healthy state.

((Comments on this story may be sent to>PDMay 20, 2013>JNM2 PHARMA.PRICEDATENOT APPLICABLE.DAY

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 20, 2013
Previous Article:i"?SciClone Pharmaceuticals signs contract with Zensun.
Next Article:i"?UCS collaborates with IBM.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters